Edwards Lifesciences (NYSE:EW) Issues Earnings Results

Edwards Lifesciences (NYSE:EW) announced its earnings results on Tuesday. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04), FiscalAI reports. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the previous year, the firm posted $0.59 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences updated its Q1 2026 guidance to 0.700-0.760 EPS.

Here are the key takeaways from Edwards Lifesciences’ conference call:

• Edwards reported a strong quarter and year with Q4 sales of $1.57 billion (+11.6%) and full‑year growth of 10.7%, and management said it has increased confidence in its 2026 guidance of 8%–10% sales growth and EPS of $2.90–$3.05; the company also holds ~ $3 billion cash and ~$2 billion remaining buyback authorization.
• TAVR remains the primary growth engine: SAPIEN TAVR sales were $1.16 billion (+10.6%) supported by long‑term PARTNER 3/2 durability data and the Early TAVR evidence, and a CMS NCD reconsideration (draft expected in June, possible final in Q4) could be a material access tailwind.
• TMTT continues rapid expansion, rising >40% to $156 million (and >$1 billion for the year) as SAPIEN M3 begins rollout, EVOQUE scales, and next‑gen PASCAL (including tricuspid) is expected in Q4 — supporting management’s $2 billion by 2030 target.
• Management increased Q4 SG&A by roughly $112 million to fund patient‑access initiatives and the AHA partnership, which contributed to a lower‑than‑expected adjusted EPS of $0.58 (GAAP $0.11 including one‑time charges); company says spending was partly delayed and will moderate in 2026.
• Longer‑term catalysts include lifetime‑management positioning (valve selection strategy), the PROGRESS moderate‑AS trial results (to be presented at TCT) and a planned preliminary surgical LAAC introduction later this year, but clinical/readout uncertainty leaves the timing and magnitude of upside unclear.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $79.01 on Thursday. Edwards Lifesciences has a 52 week low of $65.94 and a 52 week high of $87.89. The stock has a market capitalization of $45.85 billion, a PE ratio of 43.17, a PEG ratio of 2.98 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The stock’s fifty day moving average is $83.73 and its 200-day moving average is $81.13.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research reports. Sanford C. Bernstein reiterated a “market perform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research note on Monday, January 12th. Barclays reissued an “overweight” rating and set a $104.00 target price (up previously from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Piper Sandler reissued an “overweight” rating and set a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday. Finally, JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Insiders Place Their Bets

In related news, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the transaction, the vice president directly owned 38,970 shares in the company, valued at approximately $3,264,127.20. The trade was a 22.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 43,804 shares of company stock valued at $3,699,082. Insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently modified their holdings of the stock. BOKF NA raised its position in shares of Edwards Lifesciences by 9.8% in the 3rd quarter. BOKF NA now owns 2,214 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 198 shares during the period. Larson Financial Group LLC raised its holdings in Edwards Lifesciences by 8.3% in the third quarter. Larson Financial Group LLC now owns 2,948 shares of the medical research company’s stock worth $229,000 after purchasing an additional 227 shares during the period. Elevation Point Wealth Partners LLC boosted its position in shares of Edwards Lifesciences by 7.0% during the third quarter. Elevation Point Wealth Partners LLC now owns 4,071 shares of the medical research company’s stock worth $317,000 after purchasing an additional 266 shares in the last quarter. Dorsey & Whitney Trust CO LLC grew its holdings in shares of Edwards Lifesciences by 6.0% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,797 shares of the medical research company’s stock valued at $409,000 after buying an additional 272 shares during the period. Finally, Rakuten Securities Inc. raised its stake in Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after buying an additional 302 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Management raised its 2026 profit outlook and signaled robust demand for heart‑valve devices, reassuring investors about medium‑term growth prospects. This beat street hopes and helped lift the stock. Edwards Lifesciences forecasts 2026 profit above estimates on heart devices strength
• Positive Sentiment: Q4 revenue grew ~13% YoY, led by TAVR and a >40% jump in TMTT sales — evidence that core product momentum remains intact and supports the company’s sales guidance for 2026. Edwards Lifesciences Reports Fourth Quarter Results
• Positive Sentiment: Company updated Q1 2026 EPS guidance (0.700–0.760) above consensus, which reduces near‑term uncertainty and supports analyst bullishness. Edwards Lifesciences Reports Fourth Quarter Results
• Positive Sentiment: Multiple firms reiterated Buy/Overweight ratings and lifted price targets (Wells Fargo to $100, BTIG and others at ~$103), signaling strong analyst conviction and providing additional upside narrative. Benzinga
• Neutral Sentiment: Analysts and strategy writers flagged an options/contrarian trade idea following the earnings release — useful to traders but not a direct fundamental catalyst. Options Corner: Edwards Lifesciences Poor Start To The New Year Offers A Contrarian Opportunity
• Neutral Sentiment: Company earnings call and transcripts provide detail on execution and product cadence; useful for positioning but largely reiterative of management’s growth message. Edwards Lifesciences Corporation (EW) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Reported adjusted EPS missed consensus (adjusted $0.58 vs. ~$0.62), and some reports show sizable pressure on GAAP profitability and operating income — a reminder margins are under near‑term strain despite revenue growth. EW’s Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs
• Negative Sentiment: Some data vendors highlighted sharp declines in GAAP net income and notable insider selling activity; both items can weigh on sentiment if investors focus on near‑term cash/profit trends rather than adjusted metrics. Edwards Lifesciences (EW) Stock Falls on Q4 2025 Earnings

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.